massivesoli.blogg.se - Kore mou japanese

The collaboration also includes licensing Merck’s VirusExpress ® 293 Adeno-Associated Virus (AAV) Production Platform. “Our work together will focus on developing the targeted template and manufacturing for viral vectors in order to bring these life-changing therapies to more patients.” “With nearly 30 years’ experience in cell and gene therapy, we look forward to collaborating with Synplogen to further the development and manufacturing of viral vectors in Japan,” said Isao Hatano, Head of Process Solutions at Merck’s Life Science business sector in Japan. Both companies aim to integrate their capabilities to provide streamlined development, manufacturing and testing for viral vector gene therapies for Japan.

Merck, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with Synplogen, a startup spun out of Kobe University's Graduate School of Science, Technology and Innovation.

Merck to provide hands-on training to Synplogen scientists at M Lab™ Collaboration Center in Japan.

Collaboration includes VirusExpress® Platform to accelerate development and clinical research.

Merck’s Millipore® CTDMO Services (Contract Testing, Development and Manufacturing Organization) to streamline viral vector development and production in Japan.